Zhang Guoan, Wang Meng, Zhao Hongli, Cui Wen
Cancer Pathology Research Institute, Jining Medical University, Jining, Shandong 272067, P.R. China.
Department of Oncology, Shandong Jining First People's Hospital, Jining, Shandong 272111, P.R. China.
Oncol Lett. 2018 Mar;15(3):2726-2734. doi: 10.3892/ol.2017.7694. Epub 2017 Dec 27.
Axl receptor tyrosine kinase (hereafter Axl) is a member of the tyrosine-protein kinase receptor Tyro3, Axl and proto-oncogene tyrosine-protein kinase Mer family of receptor tyrosine kinases, possessing multiple different functions in normal cells. Axl is overexpressed and activated in numerous different human cancer types, triggering several signaling pathways and enhancing tumor progression. The present review assesses previous studies on the function of Axl in non-small cell lung cancer (NSCLC). Axl is overexpressed in the tumor tissues of a number of patients with NSCLC and is associated with poorer clinical outcomes; it promotes NSCLC tumor growth, invasion/metastasis, drug resistance and the epithelial-mesenchymal transition, thus providing a survival advantage to tumor cells. Therefore, Axl may be a promising target in NSCLC treatment.
Axl受体酪氨酸激酶（以下简称Axl）是酪氨酸蛋白激酶受体Tyro3、Axl和原癌基因酪氨酸蛋白激酶Mer家族的成员，在正常细胞中具有多种不同功能。Axl在多种不同类型的人类癌症中过度表达并被激活，触发多种信号通路并促进肿瘤进展。本综述评估了先前关于Axl在非小细胞肺癌（NSCLC）中功能的研究。Axl在许多NSCLC患者的肿瘤组织中过度表达，并与较差的临床结果相关；它促进NSCLC肿瘤生长、侵袭/转移、耐药性和上皮-间质转化，从而为肿瘤细胞提供生存优势。因此，Axl可能是NSCLC治疗中一个有前景的靶点。
